

**FORM 51-102F3  
MATERIAL CHANGE REPORT  
UNDER NATIONAL INSTRUMENT 51-102**

**Item 1            Name and Address of Company**

Abattis Bioceuticals Corp. (the "Issuer")  
104 - 9295 198th Street,  
Langley, B.C., V1M 3J9

**Item 2            Date of Material Change**

October 3, 2016

**Item 3            News Release**

A news release was disseminated on September 27, 2016 through the facilities of NewsFile and subsequently filed on SEDAR.

**Item 4            Summary of Material Change**

On August 22, 2016, Abattis Bioceuticals Corp. (the "**Company**" or "**Abattis**") (OTCQX: ATTFB) (CSE: ATT) to announce the appointment of Dr. Shuang Xie as its newest Science and Technology Advisor. The Company also announced the engagement of Mr. Chris Cherry as its new corporate controller. Lastly, Abattis announced the resignation of two directors Dr. Brazos Minshew and Maryam Shanjani.

**Item 5            Full Description of Material Change**

Abattis announces the appointment of Dr. Shuang Xie as its newest Science and Technology Advisor. Dr. Xie graduated from Zhejiang University in 1987 and Queen's University in 1993. Dr. Xie has been widely published and holds more than 20 patents. She has assisted companies globally in assessing project risk, securing financing, and has undertaken numerous project management mandates. Dr. Xie is a founding partner of privately-held Efilcon Corp., a leading developer and producer of extraction technologies and systems and has assisted a number of manufacturers to carry out project assessment, financing, extraction equipment set up, and extraction plant construction. She is currently appointed as overseas talent for the Chinese government and an expert consultant for Zhejiang University Innovation Research Institute.

"We are delighted that Dr. Xie has joined Abattis. Her contribution to our new strategy is already being felt," commented acting CEO Rene David." Dr. Xie's breadth of experience and depth of knowledge in extraction technologies and systems is truly remarkable. We look forward to working with Dr. Xie."

The Company also would like to express its deep appreciation for the contributions of outgoing directors Dr. Brazos Minshew and Maryam Shanjani.

Dr. Minshew has been a member of the Board of Directors and served as Abattis' Chief Science Officer since July, 2014 during which time his efforts resulted in the development of many of its current formulations, including *PhytoNOS*, which is based on the health properties of nitric oxide.

“Brazos has been a great friend and colleague to all of us here at Abattis. We wish him great success in his current endeavours,” remarked fellow director Jim Irving.

Maryam Shanjani served as Controller since March 2015 during which time she contributed immensely to restructuring and recapitalization efforts undertaken by management, enabling the Company to undertake its current growth strategy. “Maryam has been a valuable member of our management team. We appreciated her commitment and valuable contributions during the past year,” added acting CEO Rene David on behalf of the management team.

In her place, Abattis has engaged, Mr. Chris Cherry as its new corporate comptroller. Mr. Cherry has over 14 years of corporate accounting and audit experience. Mr. Cherry has extensive corporate experience and has held senior level positions for several public mining companies including Director, Chief Financial Officer, and Secretary. Mr. Cherry has been a Chartered Accountant since February 2009 and a Certified General Accountant since 2004. In his former experience as an auditor, he held positions with KPMG and Davidson and Co. LLP in Vancouver, where he gained experience as an auditor for junior public companies, and an IPO specialist.

We wish to welcome Mr. Cherry to our management team at Abattis during this important juncture of our company's history. The management of processes and maintaining a cost-effective program while we streamline our core activities will be Mr. Cherry's prime objectives.

We also wish to announce that we have moved our corporate headquarters to our administrative offices in Langley, BC. This will put our key resources under one roof while we patiently wait for the approvals of the Northern Vine Laboratories Medical Marijuana Testing Lab, which underwent final inspection in the early summer this year. All deficiencies were completed and we hope to see Northern Vine Labs as one of the only approved labs in BC shortly.

**Item 6            Reliance on subsection 7.1(2) of National Instrument 51-102**

N/A

**Item 7            Omitted Information**

N/A

**Item 8            Executive Officer**

Rene David  
CFO  
Abattis Bioceuticals Corp.  
Tel: 604.336.0881

**Item 9            Date of Report**

October 3, 2016

**Cautionary Note Regarding Forward Looking Statements**

*This material change report contains certain forward-looking statements about the Company's future plans and intentions, including statements relating to the Company's intention to implement changes across its business to achieve growth. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict", "scheduled" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect Management's current beliefs and are based on information currently available to management as at the date hereof.*

*Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking*

*statements. These factors should be considered carefully and readers should not place undue reliance on the forward looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.*